Skip to main content

Table 1 Patient Characteristics

From: Efficacy, safety and feasibility of fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in pediatric patients receiving moderately and highly emetogenic chemotherapy – results of a non-interventional observation study

Patient CharacteristicsFosaprepitant groupControl groupp-value
N = 40N = 39
n (%)n (%)
Age
 < 2 years5 (12.5)5 (12.8)0.7676
 2–6 years11 (27.5)14 (35.9)0.5752
 7–12 years11 (27.5)8 (20.5)0.6432
 13–17 years13 (32.5)12 (30.8)0.939
Sex
 Male25 (62.5)22 (56.4)0.7474
 Female15 (37.5)17 (43.6) 
Diagnosis
 ALL10 (25.0)8 (20.5)0.8359
 AML0 (0.0)1 (2.6)0.4937
 ALL relapse2 (5.0)2 (5.1)> 0.9999
 Astrocytoma1 (2.5)1 (2.6)> 0.9999
 Non-Hodgkin Lymphoma4 (10.0)5 (12.8)0.737
 Ependymoma1 (2.5)1 (2.6)> 0.9999
 Ewing’s sarcoma4 (10.0)4 (10.3)> 0.9999
 Germinoma1 (2.5)1 (2.6)> 0.9999
 Hepatoblastoma3 (7.5)2 (5.1)> 0.9999
 Hodgkin’s Lymphoma2 (5.0)1 (2.6)> 0.9999
 Medulloblastoma2 (5.0)1 (2.6)> 0.9999
 MDS1 (2.5)0 (0.0)> 0.9999
 Nephroblastoma0 (0.0)1 (2.6)0.4937
 Neuroblastoma3 (7.5)3 (7.7)> 0.9999
 Osteosarcoma1 (2.5)2 (5.1)> 0.9999
 Renal cell carcinoma0 (0.0)1 (2.6)0.4937
 Rhabdomyosarcoma4 (10.0)2 (5.1)0.6752
 T cell lymphoma1 (2.5)3 (7.7)0.3589
  1. A statistically significant difference of the patient characteristics between the two groups could not be detected (p > 0.05; Chi-square test with Yate’s correction or Fisher’s exact test)
  2. Abbreviations: ALL acute lymphoblastic leukemia, AML acute myeloid leukemia, N total number of patients per cohort, n sample size, MDS myelodysplastic syndromes